Brief Report: Identification of BACH2 and RAD51B as Rheumatoid Arthritis Susceptibility Loci in a Meta-Analysis of Genome-Wide Data

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1002/art.38183

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406772

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
BRIEF REPORT

Identification of BACH2 and RAD51B as Rheumatoid Arthritis Susceptibility Loci in a Meta-Analysis of Genome-Wide Data

Kate McAllister,1 Annie Yarwood,1 John Bowes,1 Gisela Orozco,3 Sebastian Viatte,1 Dorothée Diogo,2 Lynne J. Hocking,3 Sophia Steer,4 Paul Wordsworth,5 A. G. Wilson,6 Ann W. Morgan,7 UK Rheumatoid Arthritis Genetics Consortium, Rheumatoid Arthritis Consortium International, Joel M. Kremer,8 Dimitrios Pappas,9 Peter Gregersen,10 Lars Klareskog,11 Robert Plenge,7 Anne Barton,1 Jeffrey Greenberg,12 Jane Worthington,1 and Stephen Eyre1

Objective. A recent high-density fine-mapping (ImmuNoChip) study of genetic associations in rheumatoid arthritis (RA) identified 14 risk loci with validated genome-wide significance, as well as a number of loci showing associations suggestive of significance ($P = 5 \times 10^{-5} < 5 \times 10^{-8}$), but these have yet to be replicated. The aim of this study was to determine whether these potentially significant loci are involved in the pathogenesis of RA, and to explore whether any of the loci are associated with a specific RA serotype.

Methods. A total of 16 single-nucleotide polymorphisms (SNPs) were selected for genotyping and association analyses in 2 independent validation cohorts, comprising 6,106 RA cases and 4,290 controls. A meta-analysis of the data from the original ImmunoChip discovery cohort and from both validation cohorts was carried out, for a combined total of 17,581 RA cases and 20,160 controls. In addition, stratified analysis of patient subsets, defined according to their anti–cyclic citrullinated peptide (anti-CCP) antibody status, was performed.

Results. A significant association with RA risk ($P < 0.05$) was replicated for 6 of the SNPs assessed in the validation cohorts. All SNPs in the validation study had odds ratios (ORs) for RA susceptibility in the same direction as those in the ImmunoChip discovery study. One SNP, rs72928038, mapping to an intron of BACH2,
achieved genome-wide significance in the meta-analysis \((P = 1.2 \times 10^{-8}, \text{OR } 1.12)\), and a second SNP, rs911263, mapping to an intron of \textit{RAD51B}, was significantly associated in the anti-CCP–positive RA subgroup \((P = 4 \times 10^{-8}, \text{OR } 0.89)\), confirming that both are RA susceptibility loci.

\textbf{Conclusion.} This study provides robust evidence for an association of RA susceptibility with genes involved in B cell differentiation (\textit{BACH2}) and DNA repair (\textit{RAD51B}). The finding that the \textit{RAD51B} gene exhibited different associations based on serologic subtype adds to the expanding knowledge base in defining subgroups of RA.

Rheumatoid arthritis (RA) is a complex, chronic autoimmune disease that affects \(\sim 1\%\) of the adult population worldwide (1). In addition to inflammation of the synovial joints, RA is characterized by systemic inflammation and the presence of serum autoantibodies against citrullinated peptides (anti–citrullinated protein antibodies [ACPAs]), as defined by positive findings on the anti–cyclic citrullinated peptide (anti-CCP) antibody test (2). Genome-wide association studies have been successful in determining many loci associated with complex diseases, including RA (3). The utility of susceptibility variants within single genetic loci, in isolation, is likely to be limited, with evidence emerging that linking multiple associated genes in pathways will lead to the better understanding of differing disease mechanisms (4,5). To achieve robust pathway analysis, a comprehensive list of associated loci must be defined. Currently, 46 loci have been confirmed to be associated with complex diseases, including RA (3).

In studies of inflammatory bowel disease (IBD), the findings have become much more informative, implicating risk pathways that have not been previously recognized as important to this disease, and thus increasing the number of susceptibility markers from 92 to 163. The increased number of susceptibility loci for IBD has also enabled much more informative investigation of disease overlap. Genetic studies of RA to date, albeit successful, have not yet delivered validated evidence of novel pathways. Moreover, disease overlap studies have been limited, thus emphasizing the continuing need for discovery of disease susceptibility markers in RA.

RA is currently divided into 2 groups based on serologic subtypes, which are defined according to the presence or absence of anti-CCP antibodies, although it is still unclear whether there are biologic pathways that are common or distinct to each group (2). Determining the genetic predisposition to each serologic subtype has the potential to better define the mechanism underlying each form of disease, enabling progress toward more focused clinical management.

The most recent study aimed at identifying RA susceptibility loci (6) used a custom Illumina array (ImmunoChip), designed to interrogate 196,524 single-nucleotide polymorphisms (SNPs) for 186 loci that have been previously shown to be associated with a number of autoimmune diseases. The study by Eyre and colleagues was the first to be powered to analyze the subgroups of seronegative RA and seropositive RA separately. Genotyping in 11,475 RA cases and 15,870 controls provided evidence for 14 novel SNPs that achieved genome-wide significance, with a further 16 SNPs putatively associated with RA in a second tier of significance \((P = 5 \times 10^{-5} < 5 \times 10^{-8})\), either in an unstratified analysis or in stratified analyses of the anti-CCP antibody subgroups. We therefore tested the 16 SNPs for which there was suggestive evidence of association with RA risk in 2 independent cohorts, comprising 6,106 RA cases and 4,290 controls, and performed a meta-analysis in which we combined our results with existing data to enhance the power to identify associations in the whole data set and in subgroups stratified by anti-CCP antibody status.

\textbf{PATIENTS AND METHODS}

\textbf{ImmunoChip discovery cohort.} The characteristics of the patients in the original ImmunoChip discovery cohort (from the UK Rheumatoid Arthritis Consortium International [RACI]), as well as the genotyping and quality control procedures used for the ImmunoChip analysis, have been previously described (6). Individual-level data were available for each participant, and these data were used in the present analysis.

\textbf{Validation cohorts. UK cohort.} The UK Rheumatoid Arthritis Group (UKRAG) cohort of patients with RA was recruited from 6 centers across the UK (Table 1), as previously described (7). Genotyping was performed using the Sequenom platform.

\textbf{US cohort.} Samples from patients with RA in the US Consortium of Rheumatology Researchers of North America (CORRONA) collection and Informatics for Integrating Biology and the Bedside (I2B2) program were also tested using the ImmunoChip custom genotyping SNP array (Table 1). Principal components analysis was performed using the EigenSoft program (version 29) with HapMap phase III samples, to exclude individuals of non-European ancestry. To check relatedness between the CORRONA/I2B2 samples and the RACI ImmunoChip samples, estimates of identity-by-descent and identity-by-state allele-sharing proportions were performed in Plink, using a set of SNPs selected for high quality (missingness \(P < 0.002\), minor allele frequency [MAF] \(>0.1\)) and pruned for LD \((r^2 < 0.2\); samples were removed if the PI\_HAT value was \(>0.2\) \([n = 1 \text{ sample per pair}]\).
SNP selection/prioritization. Sixteen SNPs were selected for genotyping, based on suggestive evidence of a significant association with RA susceptibility \((P > 5 \times 10^{-8} \text{ to } P < 5 \times 10^{-5})\) in either the overall ImmunoChip genotyping analysis or in subgroups defined by the presence or absence of anti-CCP antibodies. Seven SNPs were selected from the full ImmunoChip cohort, 5 from the anti-CCP–positive subgroup, and 4 from the anti-CCP–negative subgroup.

**Statistical analysis. Stage one: validation analysis.** SNPs were included in the validation analysis if they passed quality control in both the UKRAG and US cohorts. Samples or SNPs with a call rate of <98% were removed. In addition, SNPs that did not conform to Hardy-Weinberg equilibrium \((P < 5 \times 10^{-7})\) as well as SNPs with differential missingness \((P > 0.01)\) or an MAF <0.01 were also removed. After applying all of the quality control filters, 4 SNPs (from 944 RA cases [20%] and 244 controls [9%]) failed quality control.

We tested for the association of each SNP with RA in each study independently, using logistic regression under an additive model, and then combined the results in a fixed-effects meta-analysis with inverse variance weighting (performed in Plink). The top 10 principal components were incorporated as covariates in the logistic regression analysis of the US CORRONA data set, to correct for population stratification. \(P\) values less than 0.05 were considered as evidence of a significant association in the validation cohorts.

**Stage two: meta-analysis of ImmunoChip and validation data.** The association of each SNP with RA in the original ImmunoChip analysis and in the validation analysis was tested in a fixed-effects meta-analysis with inverse variance weighting (performed in Plink). A \(P_{\text{meta-analysis}}\) threshold of less than \(5 \times 10^{-8}\) was considered significant, i.e., indicative of the discovery of a novel RA risk gene. All \(P\) values reported are 2-tailed. Heterogeneity between studies was assessed using Cochran’s \(Q\) statistic test and the \(I^2\) test. A \(P\) value for heterogeneity of less than 0.05 is suggestive of heterogeneity. The \(I^2\) test estimates the extent of heterogeneity and takes values between 0% and 100%. \(I^2\) values of 0–25% indicate low heterogeneity, 25–50% moderate heterogeneity, 50–75% high heterogeneity, and 75–100% extreme heterogeneity (8).

**Anti-CCP subset analysis.** In separate analyses of the data from the validation study and the data from the meta-analysis, we compared associations of all SNPs between controls and either anti-CCP–positive or anti-CCP–negative RA patients. In the validation study, there were 1,946 anti-CCP–positive RA patients, 720 anti-CCP–negative RA patients, and 4,290 controls. For the meta-analysis, there were 9,169 anti-CCP–positive RA patients, 4,059 anti-CCP–negative RA patients, and 20,160 controls.

**Power calculations.** All power calculations were undertaken using Quanto. The model assumed was a log additive model, and population baseline risk estimate was 1%.

**RESULTS**

In the validation analysis, 6 loci showed an association with RA susceptibility that reached significance \((P < 0.05)\): \(COG6\), \(PVT1\), \(PTPN2\), \(TNFSF4\), \(RAD51B\), and \(BACH2\) (Table 2). In the meta-analysis, 2 SNPs achieved genome-wide significance levels \((P_{\text{meta-analysis}} < 5 \times 10^{-8})\): \(BACH2\) in the full meta-analysis (Figure 1A), and \(RAD51B\) in the anti-CCP–positive subgroup (Figure 1B). These findings in the meta-analysis indicate that \(BACH2\) and \(RAD51B\) are novel validated RA risk alleles. For the remaining SNPs, all effect sizes were in the same direction as in the original ImmunoChip analysis.

In the meta-analysis, 1 SNP, rs7535176, showed evidence of high heterogeneity between studies \((I^2 = 57\%)\), and was therefore removed from further analysis. In power calculations, the average power to detect the likelihood of an association with RA at an OR of 1.12 \((P = 5 \times 10^{-8})\) was 81% in the overall validation study.
Table 2. Associations of single-nucleotide polymorphisms (SNPs) with rheumatoid arthritis susceptibility in the ImmunoChip discovery cohort, validation cohorts, and meta-analysis*

<table>
<thead>
<tr>
<th>Chr</th>
<th>SNP</th>
<th>Position (hg19)</th>
<th>Gene</th>
<th>Minor allele</th>
<th>Study</th>
<th>Study</th>
<th>Study</th>
<th>Study</th>
<th>Anti-CCP+</th>
<th>Anti-CCP−</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P</td>
<td>OR</td>
<td></td>
<td>P</td>
<td>OR</td>
</tr>
<tr>
<td>1</td>
<td>rs61828284</td>
<td>173,299,743</td>
<td>TNFSF4</td>
<td>A</td>
<td>5.5 \times 10^{-6}</td>
<td>0.83</td>
<td>0.01</td>
<td>0.81</td>
<td>1.5 \times 10^{-7}</td>
<td>0.88</td>
</tr>
<tr>
<td>2</td>
<td>rs8884275</td>
<td>172,568,120</td>
<td>CYBBD1</td>
<td>A</td>
<td>5.2 \times 10^{-5}</td>
<td>1.12</td>
<td>0.76</td>
<td>1.02</td>
<td>2.0 \times 10^{-5}</td>
<td>0.92</td>
</tr>
<tr>
<td>3</td>
<td>rs18754635</td>
<td>143,165,502</td>
<td>SLC9A9</td>
<td>A</td>
<td>1.5 \times 10^{-6}</td>
<td>0.90</td>
<td>0.004</td>
<td>1.11</td>
<td>1.1 \times 10^{-8}</td>
<td>1.12</td>
</tr>
<tr>
<td>4</td>
<td>rs79229038</td>
<td>90,796,768</td>
<td>BACH2</td>
<td>A</td>
<td>8.2 \times 10^{-7}</td>
<td>1.13</td>
<td>0.78</td>
<td>1.01</td>
<td>5.1 \times 10^{-7}</td>
<td>1.09</td>
</tr>
<tr>
<td>5</td>
<td>rs59472144</td>
<td>37,369,098</td>
<td>ELMO1</td>
<td>A</td>
<td>3.5 \times 10^{-6}</td>
<td>1.12</td>
<td>0.004</td>
<td>0.88</td>
<td>2.4 \times 10^{-7}</td>
<td>0.89</td>
</tr>
<tr>
<td>6</td>
<td>rs60512525</td>
<td>129,567,181</td>
<td>PVT1</td>
<td>G</td>
<td>2.0 \times 10^{-5}</td>
<td>0.89</td>
<td>0.024</td>
<td>0.96</td>
<td>0.022</td>
<td>0.96</td>
</tr>
<tr>
<td>7</td>
<td>rs78575308</td>
<td>102,747,941</td>
<td>TXNDC4</td>
<td>G</td>
<td>2.5 \times 10^{-5}</td>
<td>0.89</td>
<td>0.04</td>
<td>1.00</td>
<td>0.022</td>
<td>0.96</td>
</tr>
<tr>
<td>8</td>
<td>rs79932142</td>
<td>40,359,912</td>
<td>COG6</td>
<td>A</td>
<td>4.6 \times 10^{-6}</td>
<td>0.90</td>
<td>0.05</td>
<td>0.92</td>
<td>9.1 \times 10^{-7}</td>
<td>0.92</td>
</tr>
<tr>
<td>9</td>
<td>rs172300106</td>
<td>82,338,338</td>
<td>SPRY2</td>
<td>G</td>
<td>9.6 \times 10^{-6}</td>
<td>0.88</td>
<td>0.56</td>
<td>0.97</td>
<td>4.7 \times 10^{-5}</td>
<td>0.91</td>
</tr>
<tr>
<td>10</td>
<td>rs911263</td>
<td>68,753,593</td>
<td>RAD51B</td>
<td>G</td>
<td>2.3 \times 10^{-5}</td>
<td>0.89</td>
<td>0.005</td>
<td>0.88</td>
<td>4.0 \times 10^{-5}</td>
<td>0.93</td>
</tr>
<tr>
<td>11</td>
<td>rs8074003</td>
<td>76,364,493</td>
<td>SOCS3</td>
<td>A</td>
<td>1.4 \times 10^{-5}</td>
<td>0.81</td>
<td>0.44</td>
<td>0.95</td>
<td>9.2 \times 10^{-5}</td>
<td>0.86</td>
</tr>
<tr>
<td>12</td>
<td>rs62097857</td>
<td>12,857,758</td>
<td>PTPN2</td>
<td>A</td>
<td>4.5 \times 10^{-6}</td>
<td>1.22</td>
<td>0.01</td>
<td>1.20</td>
<td>1.4 \times 10^{-7}</td>
<td>1.22</td>
</tr>
</tbody>
</table>

* Association analyses of SNPs were performed using case and control data from the original ImmunoChip discovery cohort, the validation cohorts (UK and US), and the meta-analysis (ImmunoChip and validation cohorts). OR = odds ratio.
† Validation P value is presented for each SNP in the same stratification as that in the discovery study.
‡ Anti–cyclic citrullinated peptide (anti-CCP)–positive RA subgroup.
§ Anti–cyclic citrullinated peptide (anti-CCP)–negative RA subgroup.
¶ Full RA group.

41% in the anti-CCP–positive RA subset, and 6% in the anti-CCP–negative RA subset, based on an average MAF of 0.19.

**DISCUSSION**

Of the 12 loci assessed for an association with susceptibility to RA in the validation study, 2 reached accepted genome-wide significance thresholds either in the RA group as a whole or in the subset with anti-CCP antibodies, indicating that these 2 loci (BACH2, RAD51B) represent novel RA susceptibility loci. A further 4 SNPs showed evidence for validation of an association at a significance level of P < 0.05 (COG6, PVT1, PTPN2, and TNFSF4). All of the loci assessed showed effect sizes in the same direction as those in the original ImmunoChip discovery study. Of the newly confirmed RA susceptibility SNPs, rs72928038 maps to an intron of BACH2 (6q15), which has previously been associated with type 1 diabetes (9), Crohn’s disease (10), and celiac disease (11). BACH2 encodes BTB and CNC homology 1, basic leucine zipper transcription factor 2, a B cell–specific transcription factor that has been shown to regulate the BLIMP1 gene (also known as PRDM1, a validated RA susceptibility locus) in mice, which in turn influences plasma cell differentiation and promotes the antibody class switch (12). Rituximab, an effective RA treatment, inhibits CD20+ B cells, a cell subtype in which BACH2 is highly expressed.

The second novel SNP associated with RA, rs911263, was found to be significantly associated with RA risk in the anti-CCP–positive subgroup (P_{anti-CCP+ meta-analysis} = 4 \times 10^{-5}) but not in the anti-CCP–negative subgroup (P_{anti-CCP− meta-analysis} = 0.45). This SNP maps to an intron in RAD51B (14q24), which has recently been found to be associated with primary biliary cirrhosis (13). RAD51B is a gene in-

![Figure 1](image-url)
involved in the homologous recombination repair pathway of double-stranded DNA breaks. It has been demonstrated that anti-CCP–positive and anti-CCP–negative disease have differing allelic associations at the HLA locus, and identification of an association of RAD51B with anti-CCP–positive RA may add to the list of genes that differentiate between the disease subgroups, although this could not be formally proven in the present study because of the reduced power in the anti-CCP–negative cohort.

An association of 4 loci (COG6, PVT1, PTPN2, and TNFSF4) with RA risk was replicated in the validation study, at P < 0.05, but none reached genome-wide significance in the overall analysis. Given that these loci are associated with multiple autoimmune diseases, there is strong a priori evidence that these are likely to be RA susceptibility loci. Indeed, an association of RA risk with PTPN2 has now reached genome-wide significance levels, as demonstrated in an expanded, independent analysis in a European cohort (14).

The number of SNPs with suggestive evidence from the ImmunoChip analysis suggests that there are many additional undiscovered risk alleles with modest effect sizes that have yet to be formally confirmed at genome-wide significance levels of association. Power calculations showed the necessity of larger sample sizes to detect the more modest effect sizes detected in this second tier of significance, indicating that there is still great value in increasing study size to identify novel susceptibility loci. Indeed, combined sample sizes of more than 75,000 cases and controls were required to identify the 163 loci now confirmed to be associated with IBD. Sample size and power therefore remain a limitation in our current study, in particular with respect to the lack of data on the ACPA status of patients in the validation cohorts. A further limitation in this study was the targeted SNP genotyping, chosen as a cost-effective strategy to confirm putative associations. By adopting this strategy, our capacity to finely map the newly identified loci was restricted to data generated in the ImmunoChip experiment.

In conclusion, we obtained convincing evidence of 2 new RA susceptibility loci, BACH2 and RAD51B, in a combined meta-analysis of 17,581 cases and 20,160 controls, bringing the total number of novel RA susceptibility loci identified in Caucasians to 48. These findings implicate 2 distinct biologic pathways, those of B cell differentiation and DNA repair, in serologic subtypes of RA. Identification of all genetic variants that predispose to RA will increase our understanding of the molecular mechanisms involved and better annotate biologic pathway analyses.

ACKNOWLEDGMENTS

We would like to thank Edward Flynn for preparing and genotyping the UKRAG samples. We thank the RACI, the UKRAG, the CORRONA, and the I2B2 project groups for making genetic data available for this meta-analysis.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Eyre had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. McAllister, Wordsworth, Morgan, Gregersen, Klæreskog, Plenge, Barton, Worthington, Eyre.

Acquisition of data. McAllister, Diogo, Hocking, Steer, Wordsworth, Wilson, Kremer, Pappas, Gregersen, Plenge, Greenberg, Eyre.

Analysis and interpretation of data. McAllister, Yarwood, Bowes, Orozco, Viatte, Klæreskog, Plenge, Barton, Eyre.

REFERENCES